
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2021

BioSig Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-38659
(Commission File Number)

26-4333375
(IRS Employer
Identification No.)

54 Wilton Road, 2nd Floor
Westport, Connecticut
(Address of principal executive offices)

06880
(Zip Code)

(203) 409-5444
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of exchange on which registered</u>
Common Stock, par value \$0.001 per share	BSGM	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

As previously disclosed, Kenneth L. Londoner, Chairman and Chief Executive Officer of BioSig Technologies, Inc. (the “Company”), will present a slide presentation, attached hereto as Exhibit 99.1, at the Benzinga Biotech Small Cap Conference on Thursday, March 25, 2021 at 12:20 PM ET. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Slide Presentation of BioSig Technologies, Inc., dated March 2021
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 25, 2021

By: /s/ Kenneth L. Londoner

Name: Kenneth L. Londoner

Title: Executive Chairman



Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Who We Are – NASDAQ: BSGM



- EP Tech Market 13.5% CAGR*
- Global EP Market Expected to be \$12.2 Billion by 2026*
- 34 Patents Issued or Allowed
- First Customer is #1 Center by Volume in U.S.
- Razor & Blade Business Model
- FDA Cleared
- Unblinding of clinical data in 2021 expected



Data source: MarketWatch Global Electrophysiology
Device Market Could Exceed \$12.2 Billion By 2026

SYMBOL: BSGM | 3

Our Solution



More information, better decisions™

- **Signal processing platform**
- **Intracardiac signals**
- **Customizable software**
- **Artificial intelligence**


“Secret Sauce”

Physicians Can't Fix What They Can't See

PURE EP



Control



Global EP Procedures Growing Rapidly

Cardiac Ablation Procedures Are Key Hospital Revenue Drivers

Complex Cardiac Ablation:
13.5% Growth Rate

U.S.
3,425
EP labs

OUS:
3,915
EP labs

Total Global Addressable Market
\$2.0 Billion



BioSig
technologies


Published by Cardiovascular Rounds, Guggenheim Analyst – Chris Pasquale
Data source: 2018 MD&D report Advisory Board and BioSig Technologies, Inc. estimates.

SYMBOL: BSGM | 6

Expanded Product Adoption, Experience, and a Growing Database

# PURE EP Procedures by Account		# Physician Users		Diagnosis	# of Cases
Texas Cardiac Arrhythmia Institute - Austin	271	TCAI	10	Persistent AF	150
Mayo Clinic	116	Mayo	3	Paroxysmal AF	176
UNIV of Penn	89	Penn	12	PVC	70
Mass General	13	MGH	1	Ischemic VT	18
Deborah Heart & Lung	61	Deborah	2	Nonischemic VT	14
Overland Park - Kansas	53	Overland Park	4	Atypical Flutter	11
Memorial – South Bend, IN	23	Memorial	2	Atrial Tachycardia	7
Houston Methodist	17	Houston Methodist	2	AVNRT	10
First in-human - TX, IN, SC	20	First in-human - TX, IN, SC	4	Typical Flutter	8
TOTAL	663	TOTAL	40	AVRT/WPW	5

*Data as of March. 17, 2021 with a lag in some reporting
 *COVID shutdown Mar 12 - May 3
 *Diagnosis was not logged for all procedures



PURE EP™ System – Customer Installations




Hospital of the
University of Pennsylvania



Texas Cardiac Arrhythmia Institute

Business Model



Commercialization – Regions and Centers of Excellence



Florida

120 EP Programs
240 Labs

Texas

220 EP Programs
440 Labs

Northeast

175 EP Programs
400 Labs

Revenue Potential

\$286 Million



Source: Industry data and BioSig Technologies, Inc. estimates.

SYMBOL: BSGM | 10


Highly Profitable Elective Procedure

EP procedures are clinically urgent

- Delaying procedure increases stroke risk and worsens outcomes

EP is revenue generating

- CV surgery and invasive cardiology have the highest net annual revenue compared to all other service lines



Clinical Data PURE EP™ 2.0 Trial

Further establish the safety and effectiveness of the PURE EP™ System

Multi-center: **Mayo Clinic, Mass General, TCAI**

Enrollment Goal for the Primary Study Completed _____ **Q1, 2021***

Data Analysis/Unblinding of Primary Study _____ **Q1, 2021***

Primary study abstract submission _____ **Q2, 2021***

Primary study publication submission _____ **Q2, 2021***

Presentation _____ **Summer, 2021***



*These are expected dates

ClinicalTrials.gov Identifier: NCT04112433

SYMBOL: BSGM | 12

Management Team



Kenneth L. Londoner, MBA
Founder, Chairman, CEO, Director
NeuroClear Technologies; Endicott Management Partners;
J & W Seligman & Co.



Steve Chaussy, CPA
CFO
NeuroClear Technologies; Liberski Inc; Anna & Co; Penske Automotive;
Ford Hogg and Cobbe



Brenda Castrodad
Director of Human Resources
TissueTech, Inc.; HeartWare, Inc.; Schering-Plough Corp



Andy Ballou
Vice President, Investor Relations
Janney Montgomery Scott; RBC Capital Markets



Julie Stephenson, BSN, MBA
Vice President, Clinical Affairs
Medtronic; Boston Scientific; Guidant Corporation



Manasi Patwardhan
Director of Strategic Planning Verily Life Sciences,
Boston Scientific- Neuromodulation; Medtronic



Natasha Drapeau
Executive Vice President
NeuroClear Technologies; Alliance for Advancing Bioelectronic
Medicine; Institute of Directors, UK; IG Group Plc, UK



Barry Keenan, Ph.D, MBA, PMP
Vice President, Engineering
Medtronic; Nexxon MedSystems; Alfred Mann Institute for Biomedical Engineering;
Alfred Mann Foundation for Scientific Research



Todd Wiltshire
Senior Vice President, Corporate Development
Fidelity Investments; Credit Agricole; UBS; Morgan Stanley



John Kowalski
Vice President, Sales
Biosense Webster (Johnson & Johnson)



Olivier Chaudoir
Senior Director, Marketing
Biosense Webster; DePuy Synthes



Ewald Riechert
Director of Regulatory Affairs / Quality Assurance
TUV Rheinland, Siemens, Acclarent, Inc. (J&J Company)



Value Drivers

- \$28 million* in cash on the balance sheet and no debt
- Expect to triple the customer base in 2021
- Targeting sequential revenue growth in 2021
- Expect CE mark approval / EU entry 2022
- Launched AI program – Mayo partnership
- Expect presentation of data Q3 2021



 **Nasdaq: BSGM**